PATENT CLAIM ANALYSIS

Application Number: 15906350
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["514", "304000"]

Abstract:
This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.

Claim (Index 7):
The method of  claim 1 , wherein the human suffers from over-eating disorders, bulimia nervosa, binge eating disorder, compulsive over-eating, impaired appetite regulation, metabolic syndrome, type 2 diabetes, dyslipidemia, atherosclerosis, or drug-induced obesity.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 88.0
- Lexical Diversity: 1.16667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14936963', '14379032', '15058533', '15554449', '13061853']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7971469761376183
- 35 USC 102 Novelty (BERT): 0.6748693112061432
- Combined Prediction Score: 0.7849192096444708
- Mean Citation Score: 486.28498
- Max Citation Score: 738.0185
- Similarity Product: 624.6618662848473

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test